Marker Therapeutics Inc (MRKR) Stock Price, Quote & News

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1...

Industry: Biotechnology

Sector: Healthcare

Phone: 713 400 6400

Website: markertherapeutics.com

Address:

2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, United States

X600X Jun. 26 at 12:04 PM

$SLS $DRTS $MRKR $ALT

1 · Reply

kareem1988 Jun. 26 at 12:01 PM

Will this continue today? Biotech is seeing some serious momentum right now, with a few names easily clearing double digit gains Thursday. $SLS Leading the volume surge with a strong move up. $DRTS Putting together a clean breakout on heavy volume. $MRKR Flying high as the sector catches a massive growth bid. $ALT Breaking out of its base and finding strong buying support.

1 · Reply

contrast82 Jun. 25 at 3:10 PM

$MRKR Updated data from the study reported last Auqust demonstrated encouraging clinical activity with a 66% obiective response rate in relapsed non- Hodgkin lymphoma, including durable complete responses, with a favorable safety profile across evaluated doses. A data update from the APOLLO study is expected in the second quarter of 2026 Clinical studies on MT-601 in pancreatic cancer are also expected to begin in the second quarter of 2026 Marker is also conducting a phase I study on its off-the-shelf candidate. MT-401 and entered into a strategic manufacturinc collaboration with Cellipont to scale up production of MT-601...

0 · Reply

Mikole Jun. 24 at 6:23 AM

$MRKR When do you expect them to finally release some news? This is getting crazy

2 · Reply

MrDint Jun. 23 at 1:03 AM

$MRKR xbi is at 52 week high, Vera! move ya ass....deliver!

0 · Reply

Trak2 Jun. 21 at 12:47 AM

$MRKR we are wwwaayyy over due for news!!!

0 · Reply

itsMeRich Jun. 18 at 9:24 PM

$MRKR are we EVER going to hear anything from this company????

0 · Reply

flashdash Jun. 16 at 1:53 PM

$SLBT soaring.....$MRKR (MARKER THERAPEUTICS) next?.....$MRKR with T CELL therapies, low float, and a low market cap......$MRKR next ?

0 · Reply

itsMeRich May. 31 at 10:54 PM

$MRKR No ASCO poster presentation this year? Imagine that. Keep drawing your fat salaries until you need to raise and dilute us shareholders again.

0 · Reply

ineedadayoff May. 29 at 4:32 PM

$MRKR started a small position. You know they have a cure to some cancers

1 · Reply

Marker Therapeutics Quarterly report: Q1 2026

Mar 20, 2026, 8:00 AM EDT - 3 months ago

Marker Therapeutics Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 3 months ago

Marker Therapeutics Proxy statement: Proxy filing

2026-03-18T21:35:16.000Z - 3 months ago

Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)

Mar 18, 2026, 5:31 PM EDT - 3 months ago

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Marker Therapeutics Earnings release: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Marker Therapeutics Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Marker Therapeutics Proxy statement: Proxy Filing

Feb 25, 2026, 8:00 AM EST - 4 months ago

Marker Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 8:00 AM EST - 4 months ago

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-26T12:15:08.000Z - 5 months ago

Marker announces Baylor’s TACTOPS study featured on Good Morning America

2026-01-05T12:25:31.000Z - 6 months ago

Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer

Jan 5, 2026, 7:00 AM EST - 6 months ago

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

2025-12-08T13:30:08.000Z - 7 months ago

Marker Therapeutics initiated with a Buy at H.C. Wainwright

2025-11-14T12:05:51.000Z - 8 months ago

Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year

Nov 14, 2025, 7:00 AM EST - 8 months ago

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 7:00 AM EST - 8 months ago

Marker Therapeutics Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

Marker Therapeutics Quarterly report: Q3 2025

2025-11-05T12:50:27.000Z - 8 months ago

Marker Therapeutics appoints Penkus Corzo to board of directors

Nov 5, 2025, 7:30 AM EST - 8 months ago

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Nov 3, 2025, 9:15 AM EST - 8 months ago

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

2025-10-06T11:40:46.000Z - 9 months ago

Marker Therapeutics announces first patient treated in off-the-shelf program

Oct 6, 2025, 7:30 AM EDT - 9 months ago

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Sep 10, 2025, 12:30 PM EDT - 10 months ago

Marker Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:00 AM EDT - 11 months ago

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 8:30 AM EDT - 11 months ago

Marker Therapeutics Transcript: Study Update

Aug 26, 2025, 8:30 AM EDT - 11 months ago

Marker Therapeutics Press release: Study Update

Aug 26, 2025, 8:00 AM EDT - 11 months ago

Marker Therapeutics Slides: Corporate Presentation

2025-08-26T11:11:07.000Z - 11 months ago

Marker Therapeutics provides update on observations from Phase 1 APOLLO study

Aug 26, 2025, 7:00 AM EDT - 11 months ago

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Marker Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 12:30 PM EDT - 11 months ago

Marker Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

2025-06-17T12:11:26.000Z - 1 year ago

Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Slides: Corporate Presentation

2025-05-20T12:15:28.000Z - 1 year ago

Marker Therapeutics reports evidence from Phase 1 APOLLO study

May 20, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Slides: Investor Presentation

May 19, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 15, 2025, 4:00 PM EDT - 1 year ago

Marker Therapeutics Quarterly report: Q1 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

2025-03-31T12:50:08.000Z - 1 year ago

Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

Mar 31, 2025, 8:45 AM EDT - 1 year ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Annual report: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Marker Therapeutics Earnings release: Q4 2024

2025-03-05T11:32:28.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Canaccord

2025-03-05T10:17:01.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Canaccord

Feb 25, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

2025-02-10T23:05:05.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Brookline

Feb 4, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing

Feb 4, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing

Jan 13, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics Proxy statement: Proxy Filing

2025-01-10T22:15:17.000Z - 1 year ago

Marker Therapeutics files to sell 10.06M shares of common stock for holders

Jan 10, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics Registration statement: Registration Filing

2024-12-20T15:50:26.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

ARDX MRK NVO OGI UTHR VKTX

2024-12-19T13:25:36.000Z - 1 year ago

Marker Therapeutics sells 5.03M shares at $3.20 in private placement

2024-12-19T13:10:51.000Z - 1 year ago

Marker Therapeutics provides update on MT-601 patients

Dec 19, 2024, 8:06 AM EST - 1 year ago

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:05 AM EST - 1 year ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 19, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Slides: Corporate Presentation

2024-12-17T12:05:36.000Z - 1 year ago

Marker Therapeutics awarded $9.5M grant from CPRIT

Dec 17, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 10, 2024, 8:30 AM EST - 1 year ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

2024-11-27T21:30:12.000Z - 1 year ago

Marker Therapeutics files $300M mixed securities shelf

Nov 27, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Registration statement: Registration Filing

Nov 26, 2024, 11:00 AM EST - 1 year ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 14, 2024, 4:30 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 14, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Earnings release: Q3 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

May 15, 2024, 4:15 PM EDT - 2 years ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 15, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Marker Therapeutics Earnings release: Q1 2024

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Marker Therapeutics Proxy statement: Proxy Filing

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Mar 25, 2024, 5:45 PM EDT - 2 years ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Marker Therapeutics Annual report: Q4 2023

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Marker Therapeutics Earnings release: Q4 2023

Mar 22, 2024, 12:30 PM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Jan 22, 2024, 7:30 AM EST - 2 years ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 8, 2024, 8:24 AM EST - 2 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Dec 21, 2023, 11:00 AM EST - 2 years ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Nov 9, 2023, 5:00 PM EST - 2 years ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

Marker Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Marker Therapeutics Earnings release: Q3 2023

Sep 11, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Aug 30, 2023, 8:00 AM EDT - 3 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 9:03 AM EDT - 3 years ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Earnings release: Q2 2023

Aug 9, 2023, 11:00 AM EDT - 3 years ago

Marker Therapeutics Transcript: Status Update

Aug 7, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Jul 10, 2023, 7:00 AM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jun 26, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 12, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

May 31, 2023, 6:30 AM EDT - 3 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 8, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 1, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Marker Therapeutics Proxy statement: Proxy Filing

Mar 22, 2023, 8:10 AM EDT - 3 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Marker Therapeutics Annual report: Q4 2022

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Marker Therapeutics Earnings release: Q4 2022

Dec 23, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics Registration statement: Registration Filing

Dec 13, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Nov 10, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics Quarterly report: Q3 2022

Nov 10, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics Earnings release: Q3 2022

Sep 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 8, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Aug 11, 2022, 4:22 PM EDT - 4 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Quarterly report: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Earnings release: Q2 2022

$Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma$

Aug 4, 2022, 4:37 PM EDT - 4 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

May 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Quarterly report: Q1 2022

May 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Earnings release: Q1 2022

X600X Jun. 26 at 12:04 PM

$SLS $DRTS $MRKR $ALT

1 · Reply

kareem1988 Jun. 26 at 12:01 PM

1 · Reply

contrast82 Jun. 25 at 3:10 PM

0 · Reply

Mikole Jun. 24 at 6:23 AM

$MRKR When do you expect them to finally release some news? This is getting crazy

2 · Reply

MrDint Jun. 23 at 1:03 AM

$MRKR xbi is at 52 week high, Vera! move ya ass....deliver!

0 · Reply

Trak2 Jun. 21 at 12:47 AM

$MRKR we are wwwaayyy over due for news!!!

0 · Reply

itsMeRich Jun. 18 at 9:24 PM

$MRKR are we EVER going to hear anything from this company????

0 · Reply

flashdash Jun. 16 at 1:53 PM

$SLBT soaring.....$MRKR (MARKER THERAPEUTICS) next?.....$MRKR with T CELL therapies, low float, and a low market cap......$MRKR next ?

0 · Reply

itsMeRich May. 31 at 10:54 PM

$MRKR No ASCO poster presentation this year? Imagine that. Keep drawing your fat salaries until you need to raise and dilute us shareholders again.

0 · Reply

ineedadayoff May. 29 at 4:32 PM

$MRKR started a small position. You know they have a cure to some cancers

1 · Reply

CaesarZane May. 28 at 8:35 PM

$T $MRKR $MNST 🚀🚀🚀 https://youtu.be/wFA2SX4gJYo

1 · Reply

itsMeRich May. 28 at 2:58 PM

$MRKR would love to see any sort of run from this dog, so I can get the hell out.

0 · Reply

MrDint May. 26 at 9:34 PM

$MRKR if she starts to move....oh my! what a move that will be! its curling

0 · Reply

MilsLearning May. 22 at 9:11 AM

$MRKR

0 · Reply

itsMeRich May. 21 at 4:00 PM

$MRKR someone shoot this thing….. looks dead to me

0 · Reply

MrDint May. 20 at 11:27 PM

$MRKR does that mean offering incoming👇🏽?

0 · Reply

solo_soul84 May. 20 at 7:34 PM

$MRKR

0 · Reply

MrDint May. 8 at 3:49 AM

$MRKR recently?

0 · Reply

PSM_EmpowerTrading May. 7 at 6:40 PM

⏳️ Potential swing ideas 💡💡 ✅️ $MRKR recently announced positive APOLLO study, recently partnered with Cellpont for MT-601 Manufacturing, company focuses on developing novel T-cell therapies for hematological malignancies and solid tumors, HC Wainwright price target $10, WBB Securities price target $12.50, Canaccord Genuity buy rating price target $8.X, Brookline buy rating ✅️ $INAB previously announced patient 009 in phase 1 trial of INB-200 for newly-diagnosed (glioblastoma multiforme) GBM has reached a significant clinical milestone, achieving a 4-year remission, which far surpasses the progression-free outcomes observed in other clinical trials involving IDH-mutant glioma patients, Soumit Roy buy rating, analyst strong boy rating, HC Wainwright price target $6, company focuses on advancing gamma-delta (γδ) T cell-based therapies targeting cancer and autoimmune diseases

0 · Reply

seanolbrych May. 7 at 2:24 PM

$MRKR

0 · Reply

SuperGreenToday May. 6 at 3:00 PM

$MRKR

0 · Reply

Market Cap	24.51M
Revenue (ttm)	3.55M
Net Income (ttm)	-12.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-342.54%
Debt to Equity Ratio	0.00

Volume	51,323
Avg Vol	63,270
Day's Range	N/A - N/A
Shares Out	16.67M
Stochastic %K	74%
Beta	1.44
Analysts	Strong Sell
Price Target	$7.87